Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)

ClinicalTrials.gov ID: NCT06687967

Public ClinicalTrials.gov record NCT06687967. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 1:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults

Study identification

NCT ID
NCT06687967
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Sanofi
Industry
Enrollment
142 participants

Conditions and interventions

Interventions

  • Dupilumab Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 27, 2024
Primary completion
Jun 7, 2026
Completion
Aug 30, 2026
Last update posted
Jul 1, 2026

2024 – 2026

United States locations

U.S. sites
11
U.S. states
9
U.S. cities
10
Facility City State ZIP Site status
Dermatology Research Associates - Los Angeles- Site Number : 8400004 Los Angeles California 90045
Quality Care Clinical Research- Site Number : 8400034 Miami Florida 33142
Michigan Center for Research Company- Site Number : 8400013 Clarkston Michigan 48346
JDR Dermatology Research- Site Number : 8400023 Las Vegas Nevada 89145
Equity Medical- Site Number : 8400017 New York New York 10023
Onsite Clinical Solutions - Huntersville- Site Number : 8400033 Huntersville North Carolina 28078
Wake Forest University Health Sciences- Site Number : 8400028 Winston-Salem North Carolina 27104
Red River Research Partners - Fargo- Site Number : 8400007 Fargo North Dakota 58103
Center for Clinical Studies - Houston - Binz Street- Site Number : 8400011 Houston Texas 77004
MedCare Pharma - Houston - Cypress Creek Parkway- Site Number : 8400014 Houston Texas 77090
Care Access - Arlington- Site Number : 8400022 Arlington Virginia 22206

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06687967, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 1, 2026 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06687967 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →